Personalized mRNA vaccine clears pancreatic cancer in 72-year-old
Gustafson, 72, reports full quality of life and no detectable cancer after receiving a personalized mRNA vaccine that trains her immune system to attack pancreatic tumor cells. The treatment, created from her own tumor samples, is the first mRNA vaccine tested on pancreatic cancer patients and combines mRNA, genomics and artificial‑intelligence techniques. Her daughters assisted her enrollment, noting the procedure’s low statistical risk. Researchers say the trial follows a wider move toward mRNA cancer vaccines, which recently cut skin‑cancer recurrence and death by 42 %.
Key facts
- Researchers designed the vaccine from the patient’s own tumor tissue.
- The trial marks the inaugural use of an mRNA vaccine for pancreatic cancer.
- The treatment integrates mRNA, genomic sequencing and AI analysis.
- Family members assisted enrollment, emphasizing the procedure’s low risk profile.
- Broader mRNA vaccine research recently achieved a 42 % drop in skin‑cancer recurrence and mortality.
Summarised with AI from 1 sourceRead our AI policy
Why it matters
It highlights mRNA technology’s promise for treating hard‑to‑treat cancers.
What changed
First published from NPR